RxDoctor Payments Data

Brandon Lennep, MD

Advanced Heart Failure and Transplant Cardiology · Jackson, MSNPI 1073953147

Payments from drug & device makers

$19,680in general payments, 2019–2025

Across 263 payments — averaging $74.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$11K
  • Medtronic$3K
  • Abbott$2K
  • Abiomed$682
  • Novartis$410
  • Bayer$405
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$2001%
  • Speaking & faculty fees$8,86045%
  • Travel & lodging$4,38522%
  • Food & beverage$5,69429%
  • Education$5413%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$72,741
Medicare patients
258
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis41$991,168
EntrestoSacubitril/Valsartan144$125,956
JardianceEmpagliflozin69$59,048
FarxigaDapagliflozin Propanediol66$51,437
EliquisApixaban49$36,154
Isosorbide Dinitrate12$2,301
Spironolactone179$1,680
Metoprolol Succinate121$1,453
Bumetanide30$942
Eplerenone13$887
Torsemide27$732
Hydralazine Hcl37$710
Carvedilol140$654
Furosemide105$638
Digoxin31$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$10,861$1,027,32290 claims
NovartisEntresto$410$125,956144 claims
Boehringer IngelheimJardiance$260$59,04869 claims
AstraZenecaFarxiga$63$51,43766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Jackson

Where these figures come from

Is this you, or does something look wrong? →